Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4633702 | 1.00 | CTSK (0.47) | CTSKPOLBGAAMAPTXBP1 | |
| SCHEMBL7418023 | 1.00 | CTSK (0.47) | CTSKPOLBGAAMAPTXBP1 | |
| SCHEMBL5187344 | 0.97 | CTSK (0.47) | CTSKPOLBGAAMAPTXBP1 | |
| SCHEMBL5188450 | 0.97 | CTSK (0.47) | CTSKPOLBGAAMAPTXBP1 | |
| SCHEMBL9327711 | 0.96 | CTSK (0.48) | CTSKPOLBGAAMAPTXBP1 | |
| SCHEMBL7438556 | 0.95 | CTSK (0.46) | CTSKPOLBGAAMAPTXBP1 | |
| SCHEMBL7331165 | 0.95 | POLB (0.46) | CTSKPOLBGAAMAPTXBP1 | |
| SCHEMBL6622988 | 0.95 | POLB (0.46) | CTSKPOLBGAAMAPTXBP1 | |
| Potassium Ion SCHEMBL7455208 | 0.90 | POLB (0.44) | CTSKPOLBGAAMAPTXBP1 | |
| SCHEMBL7419487 | 0.86 | SYK (0.52) | CTSKPOLBTDP1SYKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101356152-A | Use of inhibitors of aureolysin in the treatment of inflammatory skin conditions characterised by colonisation with staphylococcus aureus | SERENTIS LTD (GB) | 2009-01-28 | — | — | CN | disclosed |
| US-20070049518-A1 | Novel method of treatment of inflammatory skin conditions | SERENTIS LIMITED (GB) | 2007-03-01 | — | — | US | disclosed |
| EP-0874799-B1 | PREPARATION OF ALLYL SUCCINATE DERIVATIVES AND STARTING MATERIALS THEREFOR | BRITISH BIOTECH PHARM (GB) | 2000-05-31 | — | — | EP | disclosed |
| CN-1049651-C | Metalloproteinase inhibitors | BRITISH BIOTECH PHARM (GB) | 2000-02-23 | — | — | CN | disclosed |
| US-6017889-A | Metalloproteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-01-25 | — | — | US | disclosed |
| EP-0740655-B1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 1999-10-20 | — | — | EP | disclosed |
| US-5936116-A | Preparation of allyl succinate derivatives and starting materials therefor | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-08-10 | — | — | US | disclosed |
| US-5919940-A | TERT-LEUCINE-THIAZOL-2-YLAMIDE | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-07-06 | — | — | US | disclosed |
| US-5902791-A | TREATING RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, GINGIVITIS, CORNEAL ULCERATION OR TUMOR METASTASES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-05-11 | — | — | US | disclosed |
| US-5859253-A | L-TERT-LEUCINE-2-PYRIDYLAMIDE | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-01-12 | — | — | US | disclosed |
| EP-0740652-B1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 1998-05-06 | — | — | EP | disclosed |
| US-5747514-A | Metalloproteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-05-05 | — | — | US | disclosed |
| WO-1997018183-A1 | PREPARATION OF ALLYL SUCCINATE DERIVATIVES AND STARTING MATERIALS THEREFOR | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-05-22 | — | — | WO | disclosed |
| US-5594006-A | SUCH AS COLLEGENASE, STROMELYSIN; ANTICANCER AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-14 | — | — | US | disclosed |
| CN-1138851-A | Metalloproteinase inhibitors | BRITISH BIOTECH PHARM (GB) | 1996-12-25 | — | — | CN | disclosed |
| EP-0740655-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-11-06 | — | — | EP | disclosed |
| EP-0712838-A1 | ACYLPHENYLGLYCINE DERIVATIVE AND PREVENTIVE AND REMEDY FOR DISEASES CAUSED BY INCREASED COLLAGENASE ACTIVITY CONTAINING SAID COMPOUND AS ACTIVE INGREDIENT | KANEBO LTD. (JP) | 1996-05-22 | — | — | EP | disclosed |
| WO-1995019961-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-07-27 | — | — | WO | disclosed |
| EP-0641323-A1 | CARBOSTYRIL DERIVATIVES AS MATRIX METALLOPROTEINASES INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
| WO-1994021612-A1 | CARBOSTYRIL DERIVATIVES AS MATRIX METALLOPROTEINASES INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049518-A1 | Novel method of treatment of inflammatory skin conditions | MMP8, CUTA, MMP1 | CTSK 112/4885POLB 2980/4885GAA 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.